References
Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest 39:1105–1114
Smith TJ, Hegedus L (2016) Graves’ disease. N Engl J Med 375:1552–1565
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26
Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Moutirs MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G, for the European Group on Graves’ Orbitopathy (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab 97:4454–4463
Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marinò M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ, on behalf of the European Group on Graves’ Orbitopathy (EUGOGO) (2017) Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40:547–553
Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS (2015) Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 100:432–441
Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, PignataroL Avignone S, Beck-Peccoz P (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100:422–431
Stan MN, Salvi M (2017) Management of endocrine disease: rituximab therapy for Graves’ orbitopathy—lessons from randomized control trials. Eur J Endocrinol 176:R101–R109
Wiersinga WM (2017) Advances in treatment of active moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol 5:134–142
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748–1761
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest to declare.
Ethical approval
No approval from the Institutional Ethics Committee was needed.
Informed consent
The article did not involve humans; therefore no informed consent was needed.
Rights and permissions
About this article
Cite this article
Piantanida, E., Bartalena, L. Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy?. J Endocrinol Invest 40, 885–887 (2017). https://doi.org/10.1007/s40618-017-0717-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-017-0717-8